Erich Mounce: Biosimilars and the OCM

Erich Mounce, chief operating officer, OneOncology, discusses the role that biosimilars will have in practices meeting Oncology Care Model (OCM) goals.

Transcript

Absolutely. I think so. I think that community oncology needs to embrace biosimilars. I think we have to make sure everybody's on the same page with how you consent patients for biosimilars. I think you have to understand what a biosimilar is, and that also is difficult for some practices to understand the interchangeability of that, but I absolutely think they can hit the goals. I absolutely think that biosimilars are going to transform the way we can participate in value-based contracts, whether it's OCM or a value-based contract with a payer.

Related Videos
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Ryan Haumschild, PharmD
Julie Reed
Related Content
© 2023 MJH Life Sciences

All rights reserved.